Composition for preventing, ameliorating or treating diabetic peripheral neuropathic pain comprising T2A8 compound as effective component

Abstract

The present invention relates to a composition for the prevention, improvement, or treatment of diabetic peripheral neuropathic pain comprising a T2A8 compound as an active ingredient. More specifically, when the T2A8 compound is orally administered to an animal model of diabetic peripheral neuropathic pain induced by a high-fat diet and streptozotocin, the sensitivity to mechanical pain is reduced, resulting in an excellent pain-relieving effect. Therefore, it can be usefully used as a material for pharmaceuticals or health functional foods for diabetic peripheral neuropathic pain.

Description

Technology Field

[0001] The present invention relates to a composition for the prevention, improvement, or treatment of diabetic peripheral neuropathic pain comprising a T2A8 compound as an active ingredient. Background Technology

[0002] Diabetes is a disease whose incidence is rapidly increasing worldwide. The World Health Organization (WHO) estimated that there were approximately 180 million patients with diabetes in 2008, and this number is projected to double by 2030. Consequently, the financial and social costs associated with diabetes are gradually increasing, and the mortality rate due to various complications associated with the disease is also rising. However, since strict blood sugar control can prevent the progression of the disease or slow its progression, maintaining stable blood sugar levels through lifestyle changes and appropriate treatment is considered an important approach.

[0003] Diabetic peripheral neuropathy is the most common complication of diabetes and one of the major causes of neuropathy, defined by the signs and symptoms resulting from peripheral nerve dysfunction caused by diabetes.

[0004] Diabetic peripheral neuropathy, which lowers the quality of life and increases mortality in diabetic patients, increases with age and duration of diabetes, and can occur in both type 1 and type 2 diabetic patients, but is more common in type 2 diabetic patients (32.1%) than in type 1 diabetic patients (22.7%).

[0005] Approximately 10% of diabetic patients complain of persistent pain; this pain can be spontaneous or triggered by stimuli, and it can be severe and intractable. Pain caused by diabetic peripheral neuropathy typically worsens at night and is often described as burning, stabbing, throbbing, or constricting. Furthermore, diabetic neuropathy pain is felt more distinctly in the feet than in the hands, and sometimes sudden, intense pain can lead to weight loss or depression.

[0006] Diagnosis of diabetic peripheral neuropathy involves the measurement of muscle strength, touch, temperature, and vibration, as well as the measurement of peripheral cutaneous blood flow and nerve conduction. Currently, three types of treatment are being performed for diabetic peripheral neuropathy: blood glucose control, etiological treatment, and symptomatic treatment. Based on various research results indicating a high incidence of diabetic peripheral neuropathy in diabetic patients with uncontrolled blood glucose, the correlation between hyperglycemia and the progression of neuropathy is well established, and blood glucose control is recognized as a fundamental method for the prevention and treatment of diabetic peripheral neuropathy.

[0007] Symptomatic treatments for relieving pain in diabetic neuropathy include tricyclic antidepressants, anticonvulsants, selective serotonin reuptake inhibitors (SRIs), and topical capsaicin. Tricyclic antidepressants (TCAs) alleviate pain by inhibiting the reuptake of serotonin and norepinephrine in the central nervous system, thereby suppressing pain transmission and enhancing the action of endogenous endorphins. Anticonvulsants and SRIs are used as second-line treatment options for patients for whom TCAs are not suitable. Topical capsaicin is known to be effective in relieving pain when applied topically to the skin; it alleviates pain by increasing the release of substance P from type-C nociceptive fibers at sensory nerve endings and inhibiting its reaccumulation, thereby disrupting the conduction and propagation of peripheral pain signals.

[0008] However, due to the wide variety of etiology and symptoms of diabetic peripheral neuropathy, it is difficult to find a treatment tailored to each individual patient; currently, symptomatic treatments aimed at pain relief and preventing disease progression are primarily employed rather than a fundamental cure.

[0009] Meanwhile, regarding prior art related to diabetic peripheral neuropathic pain, Korean Registered Patent No. 1802089 discloses a "pharmaceutical composition for the prevention or treatment of diabetic neuropathic pain containing GS-E3D as an active ingredient," and Korean Published Patent No. 2007-0010135 discloses a "novel use of a peptide compound for the treatment of pain in painful diabetic neuropathy." However, there has not yet been any disclosure regarding the "composition for the prevention, improvement, or treatment of diabetic peripheral neuropathic pain containing a T2A8 compound as an active ingredient" of the present invention. The problem to be solved

[0010] The present invention was derived from the above-mentioned needs, and the present invention provides a composition for the prevention, improvement, or treatment of diabetic peripheral neuropathic pain comprising a T2A8 compound as an active ingredient. More specifically, the present invention was completed by confirming that when the T2A8 compound was orally administered to an animal model of diabetic peripheral neuropathic pain induced by a high-fat diet and streptozotocin administration, the sensitivity to mechanical pain was reduced and the pain relief effect was excellent. means of solving the problem

[0011] To solve the above problem, the present invention provides a pharmaceutical composition for the prevention or treatment of diabetic peripheral neuropathic pain comprising a T2A8 compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

[0012] In addition, the present invention provides a health functional food composition for the prevention or improvement of diabetic peripheral neuropathic pain comprising a T2A8 compound represented by Chemical Formula 1 or a food-grade acceptable salt thereof as an active ingredient.

[0013] In addition, the present invention provides a feed additive for improving diabetic peripheral neuropathic pain comprising a T2A8 compound represented by Chemical Formula 1 or a food-grade acceptable salt thereof as an active ingredient.

[0014] In addition, the present invention provides a veterinary composition for the prevention or treatment of diabetic peripheral neuropathic pain comprising a T2A8 compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. Effects of the invention

[0015] The present invention relates to a composition for the prevention, improvement, or treatment of diabetic peripheral neuropathic pain comprising a T2A8 compound as an active ingredient, and more specifically, when the T2A8 compound is orally administered to an animal model of diabetic peripheral neuropathic pain induced by a high-fat diet and streptozotocin administration, the sensitivity to mechanical pain is reduced, resulting in an excellent pain relief effect. Brief explanation of the drawing

[0016] Figure 1 shows the results of measuring (A) hourly changes in blood glucose, (B) blood insulin, and (C) blood glycated hemoglobin (HbA1c) levels in the normal diet group (NFD); high-fat diet group (HFD); and high-fat diet and streptozotocin administration group (HFD+STZ). * indicates that the hourly blood glucose, blood insulin, or blood glycated hemoglobin levels of the high-fat diet group or the high-fat diet and streptozotocin administration group increased or decreased statistically significantly compared to the normal diet group, with p<0.05. Figure 2 shows the results of measuring mechanical allodynia symptoms in the normal diet group (NFD); the high-fat diet group (HFD); and the high-fat diet and streptozotocin administration group (HFD+STZ). * indicates that the withdrawal threshold values ​​of the high-fat diet group and the high-fat diet and streptozotocin administration group were statistically significantly reduced compared to the normal diet group, with p<0.05, and # indicates that the withdrawal threshold values ​​of the high-fat diet and streptozotocin administration group were statistically significantly reduced compared to the high-fat diet group, with p<0.05. Figure 3 shows the results confirming that sensitivity to mechanical pain was reduced when the T2A8 compound of the present invention was orally administered to an animal model of diabetic peripheral neuropathic pain induced by a high-fat diet and streptozotocin administration. Saline is the control group administered physiological saline. * indicates that the threshold value of the T2A8 compound administration group increased statistically significantly compared to the control group (Saline), and p<0.05. Specific details for implementing the invention

[0017] To achieve the objective of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of diabetic peripheral neuropathic pain comprising a T2A8 compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

[0018]

[0019] The above salt includes conventional acid addition salts, for example, salts derived from inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, and bromic acid, and salts derived from organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, benzoic acid, citric acid, maleic acid, malonic acid, malic acid, tartaric acid, gluconic acid, lactic acid, gestic acid, fumaric acid, lactobionic acid, salicylic acid, phthalic acid, emvonic acid, aspartic acid, glutamic acid, and acetylsalicylic acid. Additionally, the above salt includes salts derived from amino acids such as glycine, alanine, valine, isoleucine, serine, cysteine, cystine, aspartic acid, glutamine, lysine, arginine, tyrosine, and proline. In addition, the above salt includes salts of sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, and toluenesulfonic acid.

[0020] The composition of the present invention may further include pharmaceutically acceptable carriers, excipients, or diluents in addition to the active ingredient, and may be in various oral or parenteral formulations. When formulating, it is prepared using commonly used fillers, extenders, binders, wetting agents, disintegrants, surfactants, and other diluents or excipients. Solid formulations for oral administration include capsules, powders, granules, tablets, pills, etc., and these solid formulations are prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc., with one or more compounds. In addition, lubricants such as magnesium stearate and talc are also used in addition to simple excipients. Liquid formulations for oral administration include suspensions, emulsions, syrups, and aerosols; in addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients, such as humectants, sweeteners, flavorings, and preservatives. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized agents, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspension solvents. Witepsol, Macrogol, Tween 61, cocoa dough, laurin dough, and glycerogelatin may be used as bases for suppositories. For parenteral administration, it is preferable to select a method of topical application or injection via the abdominal cavity, rectum, vein, muscle, subcutaneous, intrauterine dura mater, or cerebrovascular system.

[0021] The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the level of the effective amount may be determined according to factors including the type and severity of the patient's disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects by taking all of the above-mentioned factors into account, and this can be easily determined by a person skilled in the art.

[0022] The dosage of the composition of the present invention varies depending on the patient's body weight, age, gender, health status, diet, time of administration, method of administration, excretion rate, and severity of the disease. The composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modulators.

[0023] In addition, the present invention provides a health functional food composition for the prevention or improvement of diabetic peripheral neuropathic pain comprising a T2A8 compound represented by Chemical Formula 1 or a food-grade acceptable salt thereof as an active ingredient.

[0024] In this specification, the term "acceptable salt" refers to any salt of a compound of the present invention that does not exhibit toxicity or is not unsuitable for food or pharmaceutical use while maintaining the biological properties of the compound of the present invention. Such salts may be derived from, and include, various organic and inorganic counterions known in the art. These salts include organic or inorganic acids, such as hydrochloric acid, hydrobromide, sulfuric acid, nitric acid, phosphoric acid, sulfamic acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, hexanoic acid, cyclopentylpropionic acid, glycolic acid, glutaric acid, pyruvate, lactic acid, malonic acid, succinic acid, sorbic acid, ascorbic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, chrysanthenic acid, cinnamic acid, mandelic acid, phthalic acid, lauric acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, Camponic acid, camphorsulfonic acid, 4-methylbicyclo [2.2.Acid addition salt formed with [2]-oct-2-en-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, cyclohexylsulfamic acid, quinic acid, or muconic acid, etc.; Or, it may include salts formed when an acidic proton present in the parent compound is substituted with a metal ion (e.g., alkali metal ion, alkaline earth metal ion, or aluminum ion), an alkali metal or alkaline earth metal hydroxide (e.g., sodium, potassium, calcium, magnesium, aluminum, lithium, zinc, and barium hydroxide), or ammonia, or when an organic base, such as an aliphatic, alicyclic, or aromatic organic amine, such as ammonia, methylamine, dimethylamine, diethylamine, picolin, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, N-methylglucarmine, piperazine, tris(hydroxymethyl)-aminomethane, or tetramethylammonium hydroxide, is coordinately bonded to it.

[0025] The health functional food composition for the prevention or improvement of diabetic peripheral neuropathic pain according to the present invention is preferably prepared in any one formulation selected from powder, granules, pills, tablets, capsules, candies, syrups, and beverages, but is not limited thereto.

[0026] When the health functional food composition of the present invention is used as a food additive, the T2A8 compound may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods. The amount of the active ingredient can be appropriately determined according to its purpose of use (prevention or improvement). Generally, when manufacturing food or beverages, the composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, relative to the raw material. However, in the case of long-term consumption for the purpose of health and hygiene or health control, the amount may be less than the above range, and since there are no issues regarding safety, the active ingredient may be used in an amount greater than the above range.

[0027] There are no special restrictions on the types of the above foods. Examples of foods to which the above T2A8 compound can be added include meat, sausage, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and include all health functional foods in the conventional sense.

[0028] When the composition of the present invention is used as a health beverage, it may contain various flavoring agents or natural carbohydrates as additional ingredients, as in conventional beverages. The aforementioned natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As sweeteners, natural sweeteners such as taumarin and stevia extract, or synthetic sweeteners such as saccharin or aspartame may be used. The proportion of the above natural carbohydrates is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 g of the composition of the present invention. The composition of the present invention may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the composition of the present invention may contain fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used independently or in combination. Although the proportion of these additives is not critical, the composition of the present invention is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight.

[0029] In addition, the present invention provides a feed additive for improving diabetic peripheral neuropathic pain comprising a T2A8 compound represented by Chemical Formula 1 or a food-grade acceptable salt thereof as an active ingredient.

[0030] The feed additive of the present invention corresponds to an auxiliary feed under the Feed Management Act. In the present invention, the term "feed" may refer to any natural or artificial prescribed food, single meal, etc., or the components of said single meal, intended for or suitable for animals to eat, consume, and digest. The types of said feed are not particularly limited, and feeds commonly used in the relevant technical field may be used. Non-limiting examples of said feed include plant-based feeds such as grains, root vegetables, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, meal, or grain by-products; and animal-based feeds such as proteins, inorganic substances, oils and fats, minerals, single-cell proteins, zooplankton, or food waste. These may be used individually or in a mixture of two or more types.

[0031] In addition, the present invention provides a veterinary composition for the prevention or treatment of diabetic peripheral neuropathic pain comprising a T2A8 compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

[0032] The veterinary composition of the present invention may further include suitable excipients and diluents according to conventional methods. Examples of excipients and diluents that may be included in the veterinary composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan monostearate, polysorbate 60, methylparaben, propylparaben, and mineral oil. The veterinary composition according to the present invention may further include fillers, anticoagulants, lubricants, humectants, spices, emulsifiers, preservatives, etc. The veterinary composition according to the present invention may be formulated using methods well known in the art to provide rapid, sustained, or delayed release of the active ingredient after administration to an animal, and the formulation may be in the form of powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, suppositories, sterile injectable solutions, sterile topical preparations, etc. The effective amount of the veterinary composition according to the present invention may be appropriately selected according to the individual animal. It may be determined according to the severity of the disease or condition, the sensitivity to the active ingredient of the present invention according to the age, weight, health status or sex of the individual, the route of administration, the duration of administration, factors including other compositions combined with or used simultaneously with the composition, and other factors well known in the physiological or veterinary field.

[0033] The present invention will be described in detail below by way of embodiments. However, the following embodiments are merely illustrative of the present invention, and the scope of the present invention is not limited to the following embodiments.

[0034] [Materials and Methods]

[0035] 1. T2A8 compound

[0036] The T2A8 compound (CAS no. 351898-98-1) used in the present invention was purchased from Riyun Bio Co., Ltd.

[0037] 2. Animal Management

[0038] The animal experiments conducted in this study followed the guidelines established by the Animal Ethics Committee of Gyeongsang National University (GNU-201021-M0079-01). Eight-week-old male C57BL / 6 mice were purchased from Coatec (Animal Breeding Center, Pyeongtaek, Korea). Prior to the experiment, the mice were acclimatized for one week in a specific pathogen-free environment with a 12-hour light-dark cycle. During this period, the mice were allowed to freely consume food and water within the facility.

[0039] 3. Animal Experiment Design

[0040] Mouse models combining a high-fat diet (HFD) and streptozotocin (STZ) are widely used for the study of diabetic peripheral neuropathy. First, mice were fed a high-fat diet (60 kcal%) for 2 weeks, followed by a fast of at least 8 hours, after which STZ (60 mg / kg, Sigma Aldrich, USA) was injected intraperitoneally. One week after the STZ injection, mice with a fasting blood glucose level of 250 mg / dL or higher were considered diabetic and used. They were then fed a high-fat diet for 13 weeks. Mice were randomly assigned to three groups, each consisting of a normal diet group (NFD); a high-fat diet group (HFD); and a high-fat diet and streptozotocin group (HFD + STZ), with 7 mice distributed to each group.

[0041] 4. Oral Glucose Tolerance Test (OGTT)

[0042] Mice were fasted for 8 hours in the morning and then orally administered glucose (2 g / kg). Blood was collected from the tail vein at 0, 30, 60, 90, and 120 minutes after glucose administration. Blood glucose concentrations were measured using a blood glucose meter (Optium Xceed, Abbott Diabetes Care Inc., USA).

[0043] 5. Measurement of insulin and HbA1c levels

[0044] Serum insulin levels were measured using a mouse insulin ELISA kit (Crystal Chem, Inc., IL, USA) after an 8-hour fast in mice according to the manufacturer's instructions. Absorbance was measured using a spectrophotometer (VersaMax TM Measurements were taken at 450 nm and 630 nm using a microplate reader (Molecular Devices, CA, USA). Glycated hemoglobin (HbA1c) levels were measured in whole blood collected from mice on the day of surgery using a mouse HbA1c assay kit (Crystal Chem, Inc.) according to the manufacturer's instructions. VersaMax TM Absorbance was measured at 700 nm using a microplate reader (Molecular Devices).

[0045] 6. Bonfrey Test

[0046] To measure symptoms of mechanical allodynia, experimental animals were stimulated using a calibrated Bonfrey monofilament set (EXACTA Precision and Performance Monofilament, Stoelting Co., Wood Dale, IL, USA), and avoidance responses were observed. Mice were placed in a transparent Plexiglas chamber (10 × 10 × 13 cm) with a metal mesh bottom and allowed to acclimatize for at least 30 minutes. A series of monofilaments (ranging from 0.008 to 300 g) were applied to the surface of the sole of the right hind paw using a force that bent the filament. The buckling weights of the filaments used were 0.008, 0.02, 0.04, 0.07, 0.15, 0.4, 0.6, 1, 1.4, 2, 4, 6, 8, 10, 15, 26, 60, 100, 180, and 300 g. When the mouse lifted its paw, it was recorded as a positive reaction, and the lighter filament was used for the next measurement. If there was no reaction within 10 seconds, a heavier filament was applied to evaluate sensitivity.

[0047] Mechanical sensitivity after oral administration of T2A8 (0.36 mg / kg) was measured at 1, 3, and 5 hours after administration. T2A8 was dissolved in DMSO.

[0048] 7. Statistical Analysis

[0049] Data were expressed as mean ± standard deviation (SD). To analyze differences between groups, a normality test was performed, followed by a one-way analysis of variance using Tukey's post-hoc test. Statistical analysis was performed using OriginPro 2020 software (OriginLab Corp., Northampton, MA, USA), and p-values ​​less than 0.05 were considered statistically significant.

[0050] Example 1. Establishment of a diabetic peripheral neuropathic pain model

[0051] Body weight, blood glucose, feed and water intake, and fat content were measured in a mouse model of diabetic peripheral neuropathic pain induced by high-fat diet (HFD) and streptozotocin (STZ) administration.

[0052] As a result, as disclosed in Figure 1, it was confirmed that blood glucose increased after 30 minutes in the high-fat diet and streptozotocin administration group, blood insulin levels decreased significantly, and glycated hemoglobin levels increased significantly compared to the normal diet group.

[0053] In addition, the results of the pain evaluation for mechanical allodynia confirmed that the threshold value was significantly reduced and pain increased in the high-fat diet and streptozotocin administration group (HFD+STZ) compared to the normal diet group (NFD) (Fig. 2).

[0054] Example 2. Pain relief effect following administration of T2A8 compound in a diabetic peripheral neuropathic pain model

[0055] Pain evaluation following the administration of the T2A8 compound of the present invention was performed in an animal model of diabetic peripheral neuropathic pain induced by a high-fat diet and streptozotocin administration, prepared in Example 1 above. The T2A8 compound was orally administered to the animal model at a dose of 0.3612 mg / kg, and pain was evaluated by measuring mechanical allodynia after 1, 3, and 5 hours.

[0056] As a result, as disclosed in Figure 3, it was confirmed that an analgesic effect was produced by reducing the pain response to mechanical stimulation as the administration time of the T2A8 compound increased.

Claims

Claim 1 A pharmaceutical composition for the prevention or treatment of diabetic peripheral neuropathic pain induced by a high-fat diet and administration of streptozotocin, comprising a T2A8 compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. [Chemical Formula 1] Claim 2 A pharmaceutical composition for the prevention or treatment of diabetic peripheral neuropathic pain induced by a high-fat diet and administration of streptozotocin, characterized in that, in addition to the active ingredient in claim 1, it further comprises a pharmaceutically acceptable carrier, excipient, or diluent. Claim 3 A pharmaceutical composition for the prevention or treatment of diabetic peripheral neuropathic pain induced by a high-fat diet and administration of streptozotocin, characterized in that, in claim 1, the composition is prepared in any one formulation selected from capsules, powders, granules, tablets, suspensions, emulsions, syrups, and aerosols. Claim 4 A health functional food composition for the prevention or improvement of diabetic peripheral neuropathic pain induced by a high-fat diet and administration of streptozotocin, comprising a T2A8 compound represented by the following Chemical Formula 1 or a food-acceptable salt thereof as an active ingredient.[Chemical Formula 1] Claim 5 A health functional food composition for the prevention or improvement of diabetic peripheral neuropathic pain induced by a high-fat diet and streptozotocin administration, characterized in that, in claim 4, the composition is prepared in any one formulation selected from powder, granules, pills, tablets, capsules, candies, syrups, and beverages. Claim 6 A feed additive for the improvement of diabetic peripheral neuropathic pain induced by a high-fat diet and administration of streptozotocin, comprising as an active ingredient a T2A8 compound represented by the following chemical formula 1 or a food-acceptable salt thereof. [Chemical Formula 1] Claim 7 A veterinary composition for the prevention or treatment of diabetic peripheral neuropathic pain induced by a high-fat diet and administration of streptozotocin, comprising as an active ingredient a T2A8 compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof. [Chemical Formula 1]

Images